# Jiangsu vcare pharmaceutical technology trials: 35 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with Jiangsu vcare pharmaceutical technology co., LTD as lead sponsor, 12 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Jiangsu vcare pharmaceutical technology co., LTD: 35 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/jiangsu-vcare-pharmaceutical-technology-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 18, 2026 | NCT07828639 | A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1/2 | Not yet recruiting | Non-Segmental Vitiligo | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828639) |
| September 1, 2026 | NCT07796191 | Drug-drug Interactions Studies of VC005 Tablets in Healthy Adult Subjects | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Not yet recruiting | Healthy Adult Participants | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796191) |
| August 13, 2026 | NCT07762443 | A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Recruiting | Alopecia Areata | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762443) |
| August 6, 2026 | NCT07749716 | Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Recruiting | Alopecia Areata | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749716) |
| July 28, 2026 | NCT07731685 | A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of VC004 Capsules for Pain in Bone... | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Not yet recruiting | Pain in Bone Metastases | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731685) |
| May 20, 2026 | NCT07598383 | A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in... | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Recruiting | Atopic Dermatitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07598383) |
| May 18, 2026 | NCT07592585 | Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Atopic Dermatitis | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07592585) |
| April 27, 2026 | NCT07551570 | Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Renal Impairment | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551570) |
| April 27, 2026 | NCT07551557 | Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Hepatic Impairment and Healthy Female | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551557) |
| April 16, 2026 | NCT07533851 | A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Atopic Dermatitis | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07533851) |
| January 9, 2026 | NCT07329101 | Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Atopic Dermatitis (AD) | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07329101) |
| September 15, 2025 | NCT07172360 | Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Active Ankylosing Spondylitis | 420 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172360) |
| September 15, 2025 | NCT07172347 | Efficacy and Safety Phase II Study of VC005 Tablets in Subjects With Non-segmental Vitiligo | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Recruiting | Non-segmental Vitiligo | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07172347) |
| July 16, 2025 | NCT07067775 | Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Acute Coronary Syndrome | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07067775) |
| May 15, 2025 | NCT06974292 | The Mass Balance and Biotransformation Study of \[14C\] VC005 in Chinese Healthy Adult Male Volunteers | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Atopic Dermatitis | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06974292) |
| March 24, 2025 | NCT06891040 | Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Completed | Atopic Dermatitis | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06891040) |
| December 9, 2024 | NCT06723080 | Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Moderate to Severe Atopic Dermatitis | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06723080) |
| October 26, 2024 | NCT06658353 | Phase III Clinical Study of VC004 in Patients With Localized Advanced/ Metastatic Solid Tumors | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Locally Advanced Solid Tumor | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06658353) |
| October 1, 2024 | NCT06619951 | A Clinical Trial to Evaluate the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumor | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06619951) |
| August 29, 2024 | NCT06577519 | Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | Jiangsu vcare pharmaceutical technology co., LTD | Phase 3 | Recruiting | Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI) | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06577519) |
| July 31, 2024 | NCT06529445 | Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06529445) |
| August 24, 2023 | NCT06009094 | Safety, Tolerance and Pharmacokinetics Clinical Study of VC005 in Healthy Subjects and Patients with Mild to Moderate Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Atopic Dermatitis | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06009094) |
| August 18, 2023 | NCT05997927 | Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Completed | Moderate to Severe Atopic Dermatitis | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05997927) |
| May 25, 2023 | NCT05874622 | A Phase I Clinical Study of VC005 Tablets in Subjects With Rheumatoid Arthritis. | Jiangsu vcare pharmaceutical technology co., LTD | Phase 1 | Completed | Rheumatoid Arthritis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05874622) |
| April 18, 2023 | NCT05814939 | Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis. | Jiangsu vcare pharmaceutical technology co., LTD | Phase 2 | Completed | Active Ankylosing Spondylitis | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05814939) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 21 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 3 | 5 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 21 |
| Recruiting | 9 |
| Not yet recruiting | 3 |
| Unknown | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dermatitis, Atopic | 7 |
| Acute Coronary Syndrome | 4 |
| Inflammatory Bowel Diseases | 2 |
| Neoplasm Metastasis | 2 |
| Alopecia Areata | 2 |
| Coronary Artery Disease | 1 |
| Arthritis, Rheumatoid | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Manufacturing consultants in the United States](https://specstream.ai/data/businesses/manufacturing-consultants/united-states)
- [Real estate law firms in the United States](https://specstream.ai/data/businesses/real-estate-law-firms/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Cancer treatment centers in the United States](https://specstream.ai/data/businesses/cancer-treatment-centers/united-states)
